INTERVIEW 54 FEED & ADDITIVE MAGAZINE September 2023 tridium perfringens product, we have identified the two endolysins that best target and destroy C. perfringens strains. The endolysins have been coupled with microalgae and other natural ingredients that help to deliver the performance uplift we are seeing in our trials. As part of your research, you also conduct many trials for your products. Can you share with us the details of some of the trials you have conducted and the results you have obtained? Of course, in one challenge study, mortality was reduced from 14% to below 2%, statistically matching the antibiotic control. In recent field studies the FORC3® formulation has managed to obtain FCR improvements of 4 points in an NAE farm environment. We are currently running field studies with several US producers both in NAE and non NAE settings, and are looking forward to obtaining additional data. What is the worldwide availability of the solutions you currently offer? In which regions or countries are your products available? Whilst our current focus is in the US, we are of course keen to explore opportunities to offer our solutions to other regions. We welcome the opportunity to speak with producers, feed mills operators and other members of the value chain about brining our products to markets outside the US. Are there any new topics you will focus on in the coming period and any new solutions you are preparing to launch? Yes, there are two strands to our ongoing product development: 1. Branching out into different animal species 2. Looking to address other economically important bacteria in poultry. Finally, what would you like to add? Yes, we are rapidly evolving, so if you are reading this and think what we might be doing is of interest – whether from the perspective of JV’s, Strategic Partnerships, or being an integrator in need of non-antibiotic based solutions for managing a specific pathogen – please get in touch via our website. About Kane Miller Kane Miller, EngD., obtained his engineering doctorate in biochemical engineering from University College London (UCL). It was during his postdoctoral research at UCL that he conceived the idea of applying endolysin biotechnology to animal agriculture as a potential mechanism for managing pathogens. Miller subsequently authored a successful Innovate UK government grant that, coupled with private capital, initially funded the business. Axitan now operates out of two locations. Its pilot manufacturing centre is in Georgia, USA, and its HQ & R&D centre is located within the UK’s biotech “Golden Triangle”, just outside London.
RkJQdWJsaXNoZXIy MTUxNjkxNQ==